3SBio Inc. (NASDAQ:SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has appointed Mr. Bo Tan as Chief Financial Officer, effective February 1, 2009. Since joining 3SBio in October 2008, Mr. Tan has been acting as the financial advisor for the company, providing advice on the company’s capital market initiatives and overseeing the company’s treasury functions.
Dr. Jing Lou, Chief Executive Officer of 3SBio, commented, “I am delighted to name Bo as our CFO, given both his recent contributions to 3SBio as financial advisor and the broad wealth of experience he brings, as reflected by his previous roles in the financial services industry and pharmaceutical industry. I strongly believe that his skills and experience will further benefit our company during an important time of our development.”
Mr. Tan, 36, has extensive experience within the financial and pharmaceutical industries, having worked across private equity, equity research and commercial practice. Previously, he has served as the Executive Director and a member of Investment Committee for Bohai Industrial Fund Management Company, a private equity fund in China. Earlier in his career, he spent six years in the pharmaceutical industry with Eli Lilly & Company and EMD Pharmaceuticals, Inc in North America and went on to serve as a China healthcare and consumer analyst at Lehman Brothers Asia and Macquarie Securities in Hong Kong.
Mr. Tan received his MBA degree from Thunderbird School of International Management, an MA degree in economics from the University of Connecticut and a BA degree in economics from Renmin University of China. Mr. Tan is also a CFA (Chartered Financial Analyst).